<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04505943</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/352/5/19</org_study_id>
    <nct_id>NCT04505943</nct_id>
  </id_info>
  <brief_title>Vaginal Misoprostol and Dinoprostone and Isonicotinic Acid Hydrazide Prior to Copper Intrauterine Device Insertion</brief_title>
  <official_title>Comparison of Vaginal Misoprostol and Dinoprostone and Isonicotinic Acid Hydrazide Prior to Copper Intrauterine Device Insertion in Nulliparous Women : a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of vaginal dinoprostone versus vaginal misoprostol and Isonicotinic&#xD;
      Acid Hydrazide administered before the copper intrauterine device(IUD) insertion in reducing&#xD;
      IUD inertion pain and the difficulty in inserting the IUD in nulliparous women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-acting reversible contraception methods are highly effective methods for reduction of&#xD;
      the unplanned pregnancy rate worldwide. The intrauterine device is a single procedure that&#xD;
      provides reliable, effective and long term contraception for many women. However, the&#xD;
      insertion procedure can be associated with a troublesome degree of pain that prevent some&#xD;
      women from choosing its use. Different interventions have been described to decrease pain&#xD;
      perception during intrauterine device insertion with no agreement on an effective one.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>randomized controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in visual analog scale pain scores during intrauterine device insertion</measure>
    <time_frame>10 minuts</time_frame>
    <description>The difference in pain scores during intrauterine device insertion using visual analog scale from 0 to 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the difference in visual analog scale pain scores during tenaculum application</measure>
    <time_frame>10 minuts</time_frame>
    <description>The difference in pain scores during tenaculum application using a visual analog scale from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the ease of IUD insertion</measure>
    <time_frame>10 minutes</time_frame>
    <description>the ease of IUD insertion using ease of insertion score from 0 to 10 cm (0 = very easy insertion, 10 cm = terribly difficult insertion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>women's satisfaction level: score</measure>
    <time_frame>10 minutes</time_frame>
    <description>women's satisfaction level using satisfaction score from 0 to 10 cm where 0 denotes no satisfaction and 10 denotes maximum satisfaction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>IUCD Complication</condition>
  <arm_group>
    <arm_group_label>isonicotinic acid hydrazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dinoprostone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 vaginal tablet of dinoprostone (3mg) (prostin速 E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the study nurse 12 hours before IUD insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 vaginal tablet of misoprostol (200 mcg) (Misotac速; Sigma Pharma, SAE, Egypt) inserted by the study nurse 12hours before IUD insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isonicotinic Acid Hydrazide</intervention_name>
    <description>2 vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.</description>
    <arm_group_label>isonicotinic acid hydrazide</arm_group_label>
    <other_name>INH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dinoprostine</intervention_name>
    <description>2 vaginal tablet of dinoprostone (3mg) (prostin速 E2, Pharmacia &amp; Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.</description>
    <arm_group_label>dinoprostone</arm_group_label>
    <other_name>prostin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>2 vaginal tablet of misoprostol (200 mcg) (Misotac速; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion</description>
    <arm_group_label>misoprostol</arm_group_label>
    <other_name>Misotac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  nulliparous women requesting copper IUD insertion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  Parous women,&#xD;
&#xD;
          -  contraindications or allergy to dinoprostone or misoprostol,contraindication to IUD&#xD;
             insertion,&#xD;
&#xD;
          -  untreated active cervicitis or vaginitis,&#xD;
&#xD;
          -  undiagnosed abnormal uterine bleeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>nulliparous women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>nahla w Shady, md</last_name>
    <role>Study Chair</role>
    <affiliation>Aswan universirty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hany f Sallam, md</last_name>
    <phone>+20102435461</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nahla w Shady, md</last_name>
    <phone>+201022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hanygyne@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>August 15, 2020</last_update_submitted>
  <last_update_submitted_qc>August 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>A Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

